Drug Profile

MVAX 001

Alternative Names: MVAX-001

Latest Information Update: 28 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Institute for Molecular Medicine
Developer MolecuVax
Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Exosome therapies; Immunotherapies; Peptides
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 May 2020 No recent reports of development identified for preclinical development in Cancer in USA (IV)
09 May 2016 MolecuVax in-licenses patent covering composition of matter from UniVax, LLC
11 Apr 2016 Preclinical trials in Cancer in USA (IV) before April 2016

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com